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ABSTRACT
Systemic lupus erythematosus (SLE) is a polyclonal autoimmune syndrome directed against multiple
nuclear autoantigens. Although RNA and DNA seem to have identical immunostimulatory effects on
systemic and intrarenal inflammation, each seems to differ with regard to the propensity to induce
mitogenic effects such as lymphoproliferation. To identify potential mechanisms by which DNA specif-
ically contributes to the pathogenesis of lupus nephritis, we stimulated cells with immunostimulatory
DNA or RNA in vitro and used microarray to compare the transcriptomes of RNA- and DNA-induced
genes. Immunostimulatory DNA, but not RNA, induced Mdm2, which is a negative regulator of p53. In
vivo, we observed greater expression and activation of Mdm2 in the spleen and kidneys in a mouse
model of lupus (MRL-Faslpr mice) than healthy controls. Treatment of MRL-Faslpr mice with the Mdm2
inhibitor nutlin-3a prevented nephritis and lung disease and significantly prolonged survival. Inhibition of
Mdm2 reduced systemic inflammation and abrogated immune complex disease by suppressing plasma
cells and the production of lupus autoantibodies. In addition, nutlin-3a suppressed the abnormal
expansion of all T cell subsets, including CD3CD4CD8 T cells, which associated with attenuated
systemic inflammation. However, inhibiting Mdm2 did not cause myelosuppression or affect splenic
regulatory T cells, neutrophils, dendritic cells, or monocytes. Taken together, these data suggest that the
induction of Mdm2 promotes the expansion of plasma cells and CD3CD4CD8 T cells, which cause
autoantibody production and immune complex disease in MRL-Faslpr mice. Antagonizing Mdm2 may
have therapeutic potential in lupus nephritis.
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Lupus nephritis is an immune complex glomerulo-
nephritis that develops secondary to systemic lupus
erythematosus (SLE), a polyclonal autoimmune
syndrome directed against multiple nuclear au-
toantigens.1,2 It is becoming increasingly obvious
that SLE and lupus nephritis develop from combi-
nations of genetic variants that impair proper apop-
totic cell death and rapid clearance of apoptotic cells
as a central homeostatic avenue to avoid the expo-
sure of nuclear autoantigens to the immune sys-
tem.3 The observation that antinuclear antibodies
are directed against double-stranded (ds)DNA in
the majority of SLE patients and in almost all lupus
nephritis patients first documented dsDNA as an
important lupus autoantigen. The traditional view
of nuclear particles as lupus autoantigens was re-
cently broadened by the observation that nuclear
particles promote lupus nephritis also by acting as
autoadjuvants.4,5 For example, certain endogenous
RNA or DNA particles activate Toll-like receptor
(TLR)-7 and TLR9 in dendritic cells and B cells,
which promotes lymphoproliferation and immune
complex disease as well as intrarenal inflamma-
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tion.5,6 Vice versa, neutralizing TLR7 and/or TLR9 prevents
and suppresses lupus nephritis.7–9
Although RNA and DNA seem to have identical immunos-
timulatory effects on systemic and intrarenal inflammation, some
observations suggest that RNA and DNA immune recognition
differ in terms of their mitogenic effects. For example, RNA im-
mune recognition drives mesangial cell apoptosis, whereas cyto-
solic DNA rather stimulates mesangial cell growth.10 Further-
more, administration of immunostimulatory RNA orDNA both
aggravated lupus nephritis in MRL-Faslpr mice, but only DNA
injections caused severe lymphoproliferation.11–13 We therefore
speculated that, beyond its autoantigen and autoadjuvant effects,
endogenousDNAmight have also amitogenic effect in SLE, sim-
ilar to themitogenic effect of bacterialDNA.14 BacterialDNAwas
first described in 1995 as a B cell mitogen, but the underlying
molecular mechanism has remained unknown. By using a com-
parative transcriptome analysis between RNA- and DNA-in-
duced genes, we identified the cell cycle regulator murine double
minute (Mdm)-2 to be specifically induced byDNA.Mdm2 is an
E3 ubiquitin ligase that degrades several central cell cycle regula-
tors including p53 and retinoblastoma protein.15,16 For example,
increased levels of Mdm2 prevent the induction of genes that are
required to initiate apoptosis, andMdm2directly activates the cell
cycle, twomechanisms that are well documented to contribute to
tumor progression.17,18 Most interestingly, Mdm2 induction by
DNA viruses specifically drives B cell lymphoma,19 a mechanism
thatmight contribute in a similarmanner to lymphoproliferation
in SLE, albeit initiated via self-DNA.
Therefore, we hypothesized that endogenous DNA, re-
leased from dying lymphocytes, induces Mdm2 expression
during the progression of SLE, a mechanism that promotes
inappropriate lymphoproliferation and immune complex dis-
ease including lupus nephritis. In fact, we found that Mdm2
expression and Mdm2 activation correlates with lymphopro-
liferation and lupus nephritis in MRL-Faslpr mice. Pharmaco-
logicMdm2 inhibition significantly reduced lymphoprolifera-
tion by specifically depleting the majority of autoreactive T
cells and plasma cells without affecting hematopoiesis or gran-
ulopoiesis. Mdm2 blockade also abrogated autoantibody pro-
duction, all aspects of lupus nephritis, and prolonged overall
survival in MRL-Faslpr mice. These results first document mi-
togenic effects of self-DNA in SLE, a previously unknown dis-
ease pathomechanism, which is mediated by DNA-induced
expression of the cell cycle regulator Mdm2. Our data suggest
that MDM2 inhibition could be novel therapeutic approach
for SLE and lupus nephritis.
RESULTS
Cytosolic DNA Triggers the Expression and Activation
of Mdm2
We have recently reported that cytosolic uptake of RNA and
DNA activates mesangial cells to express an almost identical
transcriptome. However, DNA but not RNA induced mesan-
gial cell proliferation10; therefore, we carefully analyzed those
few genes that were specifically induced byDNA. Among those
were several cell cycle-regulated genes of which Mdm2 was
most strongly induced only by cytosolic DNA and not by pat-
tern recognition receptor (PRR) agonists such as poly I: poly C
(pI:C) RNA (TLR3), bacterial lipoprotein (TLR2), HMGB1
(TLR2/4), and MDP (NOD1) (Figure 1, A and B). First, we
compared the capacity of different immunostimulatory RNA
and DNA formats to induce Mdm2 including DNA isolated
from calf thymus and from late apoptotic murine T cells. All
RNA and DNA formats induced IL-6 and Cxcl10 mRNA in
NIH3T3 fibroblasts (Figure 1C). However, only DNA (but not
RNA or lipopolysaccharide) significantly induced Mdm2
mRNA in a time- and dose-dependent manner (Figure 1C and
Supplemental Figure 1). This effect was DNA-specific because
DNase digestion completely prevented Mdm2 and cytokine
mRNA induction by synthetic dsDNA (Figure 1D). Cytosolic
DNA also inducedMdm2protein as well as Ser-166 phosphor-
ylation of Mdm2 (Supplemental Figure 2). Together, cytosolic
DNA including necrotic cell-derived DNA triggers the expres-
sion and activation of Mdm2.
Disease Progression in MRL-Faslpr Mice Correlates
with Increased Mdm2 Expression and Activation
MRL-Faslprmice represent a suitable model for lupus-like sys-
temic autoimmunity, and they also display the typical renal
manifestations of diffuse proliferative lupus nephritis.20 Simi-
lar to human SLE, in MRL-Faslpr mice develop splenomegaly
because of splenocyte proliferation (Figure 2, A and B). There-
fore, we first investigated Mdm2 expression in spleens of age-
matched in MRL-Faslpr and MRL control mice. Disease pro-
gression in MRL-Faslpr mice was associated with increased
Mdm2 mRNA over time compared with their age-matched
MRL controls (Figure 2C). This finding was mirrored by
Mdm2 protein expression in spleen as well as by an increased
phosphorylation of Mdm2 at Ser-166, described to indicate
Mdm2 activation in cancer cells, which was not found age-
matched MRL controls (Figure 2D and Supplemental Figure
3A). However, p53 and p53-regulated genes such as ubiquitin
D (Ubd) and Cdc25a were also increased in MRL-Faslpr mice
(Figure 2D and Supplemental Figure 3B). RenalMdm2 expres-
sion also increased, mainly due to glomerular Mdm2 expres-
sion, e.g., in podocytes (Figure 2E). Together, disease progres-
sion inMRL-Faslprmice is associatedwith increased spleen and
renal Mdm2 expression.
Mdm2 Blockade Prevents Lupus Nephritis and
Prolongs Survival of in MRL-Faslpr Mice
To determine the functional role of Mdm2 in SLE and lupus
nephritis we treated 12-week-old in MRL-Faslpr mice with
repetitive intraperitoneal injections of either vehicle or nut-
lin-3a for 4 weeks. Nutlin-3a is a small molecule that dis-
ruptsMdm2–p53 interactions and protects p53 fromMdm2
ubiquitination.21 Remarkably, 4 weeks of Mdm2 blockade
prolonged the median survival of in MRL-Faslpr mice by 10
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Figure 1. Cytosolic DNA induces Mdm2 expression. (A) Primary mouse mesangial cells were stimulated with 0.5 g of 5-triphosphate
RNA (3pRNA)/cationic lipid (CL) and 30 g of immunostimulatory DNA (ISD)/CL. Medium/CL-treated cells were used as control. After
6 hours 6 g of total RNA from three independent preparations in each group was used for gene array analysis as described.10 The
complete dataset was deposited into the GEO database (http://www.ncbi.nlm.nih.gov/geo; submission #GSE11898). Differentially
expressed probe sets between controls and 3p-RNA/CL or DNA/CL were computed using the Microsoft Excel plug-in of SAM, version
1.21. The figure shows the genes that are being induced by cytosolic DNA but not by RNA. (B and C) NIH3T3 cells were stimulated
with various formats of immunostimulatory nucleic acids complexed with or without CLs (1:1), which enhance their cytosolic uptake and
other molecular patterns: double-stranded ISD (10 g/ml); poly(dA-dT)poly(dT-dA) [poly(dA:dT)] (6 g/ml); apoptotic DNA (10 g/ml);
calf thymus DNA (6 g/ml); poly I:poly C (pI:C) (5 g/ml); double-stranded pI:CCL RNA (5 g/ml); 3pRNA (3 g/ml); lipopolysac-
charide (LPS) (4 g/ml); pam3-cys (4 g/ml); HMGB1 (0.5 g/ml); and MDP (3 g/ml). Total RNA was isolated after 6 hours, and
mRNA expression was quantified by RT-PCR. (D) NIH3T3 cells were stimulated with 10 g of double-stranded ISD complexed with
CL that had been preincubated with either medium, DNase or RNase, as described in Concise Methods. Total RNA was isolated
after 6 hours, and mRNA expression was quantified by RT-PCR. Data represent mean ratios of target mRNA to the respective 18S
rRNA  SD.
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weeks (Figure 3A). In a second cross-sectional study we
obtained urine, plasma, and tissues from vehicle- and nut-
lin-3a-treated MRL-Faslpr mice at 16 weeks of age. A signif-
icant reduction of the urinary albumin-creatinine ratio in-
dicated a protective effect of Mdm2 blockade on lupus
nephritis (Figure 3B). In fact, Mdm2 blockade prevented
the diffuse proliferative lupus nephritis of in MRL-Faslpr
mice as evidenced by a reduction of the
activity and chronicity indices, normally
used for scoring of human lupus nephri-
tis (Figures 3, C and D). Mdm2 blockade
also significantly reduced autoimmune
peribronchitis in lungs (Figures 3, C and
D). Together, Mdm2 blockade prevents
lupus nephritis and prolongs survival of
in MRL-Faslpr mice.
Mdm2 Blockade Suppresses the




from lupus nephritis was associated with a
significant reduction of glomerular IgG de-
posits, suggesting that nutlin-3a also af-
fected systemic immune complex disease
(Figure 3, C and D). SLE-related immune
complex disease largely depends on the
hyperactivation of plasma cells and lupus
autoantibody production; hence, we
tested this aspect of systemic autoimmu-
nity in vehicle- and nutlin-3a-treated
MRL-Faslpr mice. Mdm2 blockade with
nutlin-3a reduced plasma IgG levels in-
cluding all IgG isotypes except IgG3
(Figure 4A).Nutlin-3a also reduced plasma
dsDNA autoantibodies as quantified by
ELISA (Figure 4B). The latter was validated
by Crithidia luciliae kinetoplast staining,
which was almost absent in nutlin-3a-
treated MRL-Faslprmice at a plasma dilu-
tion of 1:20 (Figure 4C). In addition,
plasma from vehicle-treated MRL-Faslpr
mice displayed a diffuse nucleoplasmic
staining pattern of interphase Hep2 cells,
i.e., characteristic of dsDNA autoantibod-
ies (Figure 4C). This staining pattern was
no longer observed with plasma from nut-
lin-3a-treated MRL-Faslpr mice so that
rim-like and coarse granular nucleoplas-
mic staining patterns became visible. These
are characteristic for antibodies directed
against lamin-B along the nuclear mem-
brane22 or against the spliceosome, i.e.,
U1snRNP and Smith antigen, respectively
(Figure 4C). In addition, splenocyte flow cytometry revealed
that Mdm2 blockade specifically reduced CD138  light
chain plasma cells (Figure 4D). To dissect this effect on long-
and short-lived plasma cells, some MRL-Faslpr mice were in-
jected with bromodeoxyuridine (BrdU) 1 week before they
were killed.23Mdm2 blockade reduced both the BrdU negative
long-lived and the BrdU positive short-lived plasma cells (Fig-
Figure 2. Mdm2 induction and activation in lupus mice. Fas deficiency in MRL mice is
associated with significant splenomegaly (A) and lymphocyte proliferation, as indicated
by positivity of parafollicular lymphocytes for the proliferation marker Ki-67 (B). Orginial
magnification, 100. Images are representative for 12 mice in each group. (C) Spleen
Mdm2 mRNA levels were quantified by RT-PCR in MRL wild-type (WT) and MRL-Faslpr
mice at various time points as indicated (n  4 for each genotype per time point). *P 
0.05, **P  0.01 versus age-matched WT mice. (D) Immunoblotting for spleen protein
extracts of mentioned groups were performed using specific antibodies for Mdm2,
Ser-166 phosphorylation of Mdm2, p53, Ser-15 phospho p53, and -actin. (E) Semi-
quantitative assessment of Mdm2 protein expression in glomerular and tubulointersti-
tial sections of kidney stained for Mdm2. Mdm2 staining was scored from 0 to 3 per 15
glomeruli or per 15 high-power fields.
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Figure 3. Mdm2 blockade reduces kidney as well as lung injury and mortality in experimental lupus. (A) Survival was shown as
Kaplan-Meier curve, and the treatment period is indicated by dotted lines. Note that 4 weeks of Mdm2 blockade extended median
survival by 10 weeks. n  8 mice in each group. (B) Albuminuria, a functional parameter of lupus nephritis, was quantified in urine
samples from at least 12 mice in each group. The ratio of urinary albumin per respective creatinine excretion was calculated to correct
for the variability of urine concentration by different fluid intake as done in human urine analysis. (C) Renal (a and b) and lung (c) sections
were stained with PAS or IgG as indicated. Images represent at least 12 mice in each group. Note that nutlin-3a reduced glomerular
IgG staining (a), diffuse proliferative lupus nephritis (b), and peribronchial inflammation (c) in MRL-Faslprmice. (D) Lupus nephritis activity
and chronicity scores were assessed on Periodic acid-Schiff (PAS)-stained renal and lung sections as described in Concise Methods
(score ranged from 0 to 24 and 0 to 12, respectively). Data represent means SD from at least 12 mice in each group. *P 0.05 versus
vehicle-treated MRL-Faslpr mice ; **P  0.01; ***P  0.001.
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ure 4D), indicating that Mdm2 is a nonre-
dundant factor for plasma cell proliferation
in SLE. Together, Mdm2 blockade protects
from lupus nephritis because it suppresses
the hyperproliferation of plasma cells, lu-
pus autoantibody production, and lupus-
like immune complex disease of the kidney.
Mdm2 Blockade Also Depletes CD4/
CD8 Double-Negative T Cells without
Causing Myelosuppression
The profound effect of Mdm2 blockade
on plasma cell proliferation raises the
question whether these antiproliferative
effects are specific or rather unspecific,
the latter involving the risk for B and T
cell ablation and diffuse myelosuppres-
sion. We used flow cytometry to deter-
mine which splenocyte populations were
affected by Mdm2 blockade. Nutlin-3a
had no effect on B220 IgDIgMma-
ture B cells, B220 CD21low CD23high
follicular B cells, or B220CD21high
CD23low marginal zone B cells, but it re-
duced CD3CD4, CD3CD8, and
CD3/CD4CD8 double-negative T
cells (Table 1). This nutlin-3a effect was
sufficient to substantially reduce the
spleen weight size and showed a trend to-
ward lower weights of mesenterial lymph
nodes, documenting that Mdm2 drives
lymphoproliferation in SLE (Supplemen-
tal Figure 4, A and B). However, it is of
note that Mdm2 blockade did not affect
the numbers of CD4/CD25/Foxp3
“regulatory” T cells, CD11c dendritic
cells, monocyte/macrophages, and neu-
trophils (Table 1). Furthermore, nut-
lin-3a treatment did not affect the total
number of cells in femur bone marrow or
the numbers of bone marrow monocyte/
macrophages, neutrophils, and plasma
cells as well as white and red cell counts in
peripheral blood (Table 1). Thus, Mdm2
blockade prevents from lupus nephritis
by suppressing the expansion of CD3/
CD4CD8 double-negative T cells and
plasma cells in lymphoid organs, but it
does not affect myelo- or hematopoiesis.
Necrotic Cells Induce Mdm2
Expression
So far our data show that Mdm2 induc-
tion drives lymphoproliferation and au-
toimmunity in SLE from which lupus ne-
Figure 4. Mdm2 blockade affects autoantibodies in experimental lupus. (A) Plasma
levels of total IgG or respective IgG isotype antibodies were quantified by ELISA. Data
are means of at least 12 mice in each group  SD. *P  0.05, **P  0.01, ***P  0.001
versus vehicle-treated MRL-Faslpr mice. (B) Plasma anti-double-stranded DNA (dsDNA)
IgG was quantified by ELISA from at least 12 mice in each group. (C) The specificity of
anti-dsDNA IgG was confirmed by positive kinetoplast staining (in green) of Crithidia
luciliae, evident by costaining with nuclear DAPI signals (in blue). Note that nutlin-3a
reduced the green IgG (but not the blue DAPI) signal (left panel). Hep2 cell staining
(right panel) identified antinuclear antibodies with different patterns in both of the
groups (see text for details). Images are representative for at least 12 mice in each
group. (D) Splenocyte plasma cell subsets in vehicle- or nutlin-3a-treated MRL-Faslpr
mice were quantified by flow cytometry. BrdU uptake was used to discriminate long-
and short-lived forms of CD138  light chain plasma cells in spleen. Histogram
profiles of bromodeoxyuridine (BrdU) intensity of gated CD138  light chain plasma
cells (left) and the quantitative BrdU plasma cell data (right). Data are means SD from
at least six mice in each group. *P 0.05, **P 0.01 versus vehicle-treated MRL-Faslpr
mice. n  6.
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phritis develops. However, what is the source of
immunostimulatory DNA in MRL-Faslpr mice? Dead cell
clearance defects and increased levels of extracellular nu-
clear autoantigen are a hallmark of systemic lupus24,25 and
drive disease activity, e.g., via the immunostimmulatory ef-
fects of endogenous nucleic acids.4,5 In MRL-Faslpr mice ne-
crotic (propidium iodide positive) cells accumulate in spleens
compared with their wild-type counter parts (Figure 5A). This
phenomenon associates with increased mRNA levels of
IFN- and IFN- in the same organ (Figure 5B). Therefore,
we speculated that necrotic cell-derived DNA can induce
the expression of Mdm2. To test this, we exposed necrotic
supernatants to cultured NIH3T3 fibroblast cells and mea-
sured Mdm2 expression. Interestingly necrotic cell super-
natants inducedMdm2 expression along with inflammatory
molecules such as Cxcl10 and IL-6, all of which were signif-
icantly reduced by DNAse digestion of the necrotic cell su-
pernatants (Figure 5C). Immunostimulatory DNA (but not
RNA) increased cell proliferation, which was inhibited by
nutlin-3a (Figure 5D). In support of these in vitro results,
Mdm2 blockade significantly reduced the amount of pro-
pidium iodide-positive “secondary necrotic” cells in spleens
of MRL-Faslpr mice and increased the number of annexin
V-positive “apoptotic” cells (Figure 6A), suggesting that the
cell cycle inhibitory and proapoptotic effect of nutlin-3a not
only inhibits splenocyte proliferation but also secondary
splenocyte necrosis as a stimulus for DNA-mediated Mdm2
induction. Less splenocyte necrosis with nutlin-3a treat-
ment was also associated lower spleen mRNA expression
levels of TNF, IFN- and IFN-, which mirrors the reduc-
tion of the respective serum levels of these factors in the
plasma of nutlin-3a-treated MRL-Faslpr mice (Figure 6, B
and C). Together, MRL-Faslpr mice secondary-necrotic
splenocytes releases DNA, which induced Mdm2. Mdm2
drives splenocyte proliferation as well as additional spleno-
cyte necrosis. Nutlin-3a blocks both mechanisms, which re-
duced systemic inflammation as well as lymphoprolifera-
tion, autoimmunity, and lupus nephritis.
DISCUSSION
Our experiments identify a previously unknown pathogenic
effect of self-DNA in lupus nephritis, i.e., a mitogenic effect
that is specifically mediated via the induction of Mdm2. So
far the pathogenic role of self DNA for lupus nephritis was
referred to its functional properties as an autoantigen as
well as an autoadjuvant.2,5 Recently, it was concluded that
lupus develops because genetic variants of dead cell clear-
ance allow the exposure of potential nuclear autoantigens to
the immune system where they are—by mistake—taken as
viral particles, elicit autoadjuvants effects, and thereby trig-
ger complex pseudoantiviral immune responses.4 The mi-
togenic effect of self-DNA, which we describe here, adds
another DNA-related pathomechanism and identifies
Mdm2 as a novel target gene in lupus nephritis.
The current pathogenic concept of lymphoproliferation
in SLE is based on the antigenic properties of nucleosomes
and ribonucleoproteins released from dying cells, which
drive the expansion of epitope-specific autoreactive lym-
phocytes.25 However, epitope spreading and polyclonal au-
toimmunity suggest additional mechanisms of lymphopro-
liferation in SLE.1,25 We found splenocyte necrosis to be
associated with splenocyte proliferation, both correlated
with the induction and activation of Mdm2. These findings
differ from a previous report describing that DNA breaks
induced by radiation inhibit Mdm2 and promote p53-de-
pendent cell death.26 The causal role of Mdm2 in the rela-
tionship of splenocyte necrosis and proliferation was docu-
mented by Mdm2 inhibition, which reduced splenocyte
necrosis and increased “immunologically silent” apoptotic
cell death. We assume that Mdm2 inhibition disrupted the
vicious cycle for additional release of immunostimulatory
molecules.27 The antiproliferative effect of nutlin-3a af-
fected CD4/CD8 double-negative T cells and plasma cells
but not B cells in spleen or myelo- and hematopoiesis in the
bone marrow. The decline in B220 cells in spleen might
also results from a reduction of natural killer (NK) cells,




Total number of cells 460.61  57.15 291.21  43.55a
Marginal zone B cells 10.34  4.27 10.57  2.31
Follicular B cells 20.32  7.79 19.45  1.66
Mature B cells 37.34  12.40 38.42  7.86
Monocytes 0.97  0.31 0.83  0.12
Neutrophils 0.94  0.28 0.51  0.14
CD3CD4 cells 10.59  3.10 4.60  0.70a
CD3CD8 cells 2.16  0.45 0.90  0.11a
CD3CD4CD8 cells 19.19  3.29 6.27  2.43a
Regulatory T Cells 11.55  2.87 9.13  0.85
Dendritic cells 19.15  4.03 12.54  3.56
Macrophages 18.27  3.43 16.10  1.94
Bone marrow (cells/million)
in femur
Total number of cells 61.84  9.77 83.25  8.29
Monocytes 5.25  1.20 9.95  1.11
Neutrophils 35.02  5.46 49.76  3.59
Plasma cells 0.26  0.10 0.28  0.03
Short-lived plasma cells 0.11  0.03 0.09  0.02
Long-lived plasma cells 0.14  0.06 0.19  0.01
Blood
Neutrophils (cells/l) 2096.27  221.38 2123.6  389.12
Lymphocytes (cells/l) 4029.72  872.10 4176.8  1103.5
Monocytes (cells/l) 427.9  110.1 462.08  164.3
Eosinophils( cells/l) 54.27  14.7 28.25  9.8
Leukocytes (109 cells/L) 6.37  1.1 6.79  1.4
Erythrocytes (1012 cells/L) 9.18  0.15 8.96  0.23
Thrombocytes (109 cells/L) 954  63.8 1187  82.1
n  6 per group; data are means  SEM; aP  0.05 versus vehicle.
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which we did not specifically quantify in our analysis. Bone
marrow long-lived plasma cells that assure the humoral
component of immune memory were also not affected. The
latter could be explained by low numbers of necrotic cells in
bone marrow and the fact that the nutlin-3a concentrations
reached in bone marrow are much lower compared with
other organs.28 The specific effect of Mdm2 inhibition on
lymphocyte expansion and the reduction of autoantibodies
Figure 5. DNA content of necrotic cells induced Mdm2 expression. (A) The graph shows annexin V- and/or propidium iodide
(PI)-positive splenocytes from 18-week-old MRL-wild-type (WT) and MRL-Faslpr mice that were quantified by flow cytometry and are
shown in representative dot blots (n  4 mice). (B) IFN- and IFN- expression in spleens of MRL-Faslpr mice and MRL-wild-type (WT)
mice. Data represent in mean ratios of target mRNA to the respective 18S rRNA  SD. (C) NIH3T3 cells were stimulated with necrotic
cell supernatants (NS) complexed with cationic lipids (CLs) and DNase-treated necrotic supernatants (NSDNase). Total RNA was
isolated after 6 hours, and mRNA expression was quantified by RT-PCR. (D) Nutlin-3a-treated or untreated NIH3T3 cells were
stimulated with double-stranded immunostimulatory DNA (ISD) complexed with CL or double-stranded poly I:poly C (pI:C) RNA
complexed with CL (Lipofectamine 2000 1:1) at the indicated concentrations for 48 hours, and cell proliferation was quantified
with 96 Aqueous One Solution Cell Proliferation Assay. The data represent the mean  SD of three independent experiments.
*P  0.05, **P  0.01, t test , ***P  0.001.
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indicate the therapeutic potential of Mdm2 inhibitors in
SLE without systemic immunosuppression. Consistent with
many other interventional lupus nephritis studies the re-
duction of autoreactive lymphocytes correlated with re-
duced production of immune complex disease and lupus
nephritis. Finally, the functional role of Mdm2 induction in
lupus was documented by a significant prolongation of
overall life span of MRL-Faslpr mice, although few mice in
the nutlin-treated group died and the un-
derlying cause could not be determined.
However, the survival benefit of nutlin-
3a-treated over untreated MRL-Faslpr
mice exceeded the treatment period three
times; hence, we conclude that Mdm2
blockade has a profound effect on the
phenotype of MRL-Faslpr mice.
The finding that necrotic cell-derived
DNA induces cell proliferation viaMdm2
induction could represent a basic physi-
ologic mechanism to trigger tissue regen-
eration after necrotic cell injury.29 This
mechanism would be in contrast to the
homeostatic process of apoptotic cell
death, which avoids DNA release and
which is not associated with cell prolifer-
ation.30 However, Mdm2-induced cell
proliferation is already well known to
turn into a maladaptive pathomecha-
nism, i.e., in cancer malignancy. A broad
literature describes the pathogenic role of
Mdm2-mediated p53 stabilization for an
uncontrolled proliferation of malignant
cells.17,18 It is of note that several DNA
(not RNA) viruses have the potential for
an oncogenic transformation of infected
cells, such as Epstein-Barr virus and Ka-
posi‘s sarcoma herpesvirus for B cell lym-
phoma, a process that can also be pre-
vented by Mdm2 inhibition.19,31,32 In
fact, the central role of Mdm2 in cancer
served as the rationale for the develop-
ment of Mdm2 inhibitors, which were
proven to be effective in inducing cancer
cell apoptosis.21,33–35 Hence, nutlin-3a is
currently in clinical trials for the treat-
ment of various cancers.34,35
Our data document an inappropriate
induction of Mdm2 in murine SLE,
which contributes to the autoimmune
polyclonal lymphoproliferation, similar
to virus-induced lymphoma. SLE may
therefore represent a second example
how DNA-induced Mdm2 and subse-
quent cell proliferation can turn into a
maladaptive pathomechanism. This pro-
cess would be similar to the molecular mimicry of self and
viral nucleic acids at the level of the Toll-like receptors by
which nuclear particles induce those autoadjuvant effects
that drive the presentation of lupus autoantigens.5,6,36 In
addition, it might be possible that persistent DNA virus
replication, e.g., Epstein-Barr virus, serves as a second
source of mitogenic DNA driving lymphoproliferation in
lupus as it has been proven for Epstein-Barr virus-induced
Figure 6. Nutlin-3a reduced necrotic cells in MRL-Faslpr mice. (A) Annexin V and/or
propidium iodide (PI)-positive splenocytes from 16-week-old vehicle- or nutlin-3a-
treated MRL-Faslpr mice were quantified by flow cytometry and are shown in repre-
sentative dot blots (left) and as a histogram (right). (B) Twelve-week-old MRL-Faslpr
mice were treated either with vehicle or nutlin-3a for 4 weeks, and spleen mRNA levels
of IFN-, IFN-, and TNF were quantified by RT-PCR. Data represent mean ratios of
cytokine mRNA/18s rRNA  SD from at least 12 mice in each group. (C) Plasma levels
of IL-12, IFN-, and TNF were measured by ELISA. Data are means of at least 12 mice
in each group  SD. *P  0.05, **P  0.01, ***P  0.001 versus vehicle-treated
MRL-Faslpr mice.
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lymphomas.19,36 Furthermore, it is intriguing to speculate
that Mdm2 induction is also responsible for the recently
described phenomenon of TLR7/9-mediated expansion and
steroid resistance of plasmacytoid dendritic cells in lupus.37
Together, the progression of SLE is associated with
Mdm2 induction, most likely triggered by necrotic cell-re-
leased DNA.Mdm2 induction promotes the abnormal poly-
clonal expansion of autoreactive lymphocytes, which causes
autoantibody production and immune complex disease in
murine lupus. We conclude that the mitogenic effect of self-
DNA via Mdm2 induction is a previously unknown patho-
mechanism in SLE and lupus nephritis. Hence, Mdm2 inhi-




Six-week-old female MRL-Faslpr mice from Harlan Winkelmann
(Borchen, Germany). At 12 weeks of age the mice received intra-
peritoneal injections every other day with either the Mdm2 antag-
onist nutlin-3a (Alexis Biochemicals, San Diego, CA) at a dose of
20 mg/kg body wt in DMSO or vehicle only for 4 weeks. All exper-
imental procedures were performed according to the German an-
imal care and ethics legislation and had been approved by the local
government authorities. All mice were killed by cervical disloca-
tion at the end of the 16th week of age, and tissues, urine, and
plasma were harvested for a comparative analysis. In a second
identical experiment survival was assessed beyond the aforemen-
tioned treatment interval.
In Vitro Studies
Primary mesangial cells were cultured as described previously.10
NIH3T3 cell line obtained from ATCC (American Type Culture
Collection). Cells were maintained in Dulbecco’s modified Eagle’s
(DME) medium (Biochrom KG, Berlin, Germany) supplemented
with 10% fetal bovine serum, penicillin 100 U/ml, and streptomy-
cin 100 g/ml at 37°C in a humidified incubator containing 5%
CO2. Necrotic cell supernatants were prepared from EL4 cells ei-
ther by repeated freezing and thawing or staurosporine treatment
for 24 hours.38 In some experiments necrotic soup was treated with
DNAse (Qiagen) for 1 hour at 37°C. Apoptotic DNA was prepared
from staurosporine-treated EL4 cells for 12 hours, and DNA
was isolated with apoptotic DNA ladder kit (Roche, Mannheim,
Germany). We purchased calf thymus DNA, pdA:dT [poly
(dA-dT)poly(dT-dA)] sodium salt (Sigma-Aldrich) pI:C RNA,
Pam3Cys, MDP (Invivogen), and HMGB1 protein (Novus Biolog-
icals). Immunostimulatory DNA and 5-triphosphate RNA were
prepared as described previously.11 Cell proliferation was deter-
mined using CellTiter 96 Aqueous One Solution Cell Proliferation
Assay (Promega, Madison, WI). Briefly, NIH3TC cells were grown
in 96-well plates for 24 hours before stimulation with immunos-
timulatory DNA and pI:C cationic lipid (CL). Cells were treated
with nutlin-3a (1 M) before 1 hour of stimulation. After 72 hours
the solution was added, and cells were incubated at 37°C in 5%
CO2 for 2 hours before absorbance was determined at a wave
length of 492 nm.
Microarray Studies
RNA was prepared from murine primary mesangial cells that had
been stimulated with 0.5 g of 3P-RNA/CL and 30 g of non-CpG
DNA/CL for 6 hours as described.10 Biotin-labeled cRNA samples
were hybridized with MOE 430Av2 arrays and analyzed using the
Affymetrix GeneChip Operating software (GCOS1.0). Assay quality
and normalization was performed, and probe set signals were loga-
rithmized to base 2 as described.10 To exclude probe sets in the lower
end of the signal range, which have large signal variation, a back-
ground filter cutoff value was defined as the maximal signal value
obtained from nonhuman Affymetrix-control probe sets multiplied
by a factor of 1.2. Probe sets with a signal below cutoff in every array of
the corresponding comparison as well as Affymetrix control probe
sets were excluded from the analysis. The dataset was deposited into
the GEO database (http://www.ncbi.nlm.nih.gov/geo; submission
#GSE11898).Differentially expressed probe sets between controls and
3P-RNA/CL or non-CpG DNA/CL were computed using the Mi-
crosoft Excel plug-in of SAM, version 1.21.
Immunoblotting
Immunoblotting was performed for Mdm2 (Abcam, Cambridge,
U.K.), Ser-166 Phospho Mdm2, p53, Ser-15 phospho p53, and -ac-
tin (Cell Signaling Technology, Beverly, MA) as described previ-
ously.10
Flow Cytometric Analysis
We prepared single-cell suspensions from femoral bone marrow and
spleen. We performed flow cytometric analyses of splenocytes and
bone marrow cells using fluorochrome-conjugated antibodies to
mouse CD3, CD4, CD8, CD25, CD21, CD23, B220, CD138, CD11c,
CD40, IgD, IgM, 7/4 (neutrophils), and Ly6G (all purchased fromBD
Biosciences, Heidelberg, Germany) and F4/80 (Ebioscience, Frank-
furt, Germany). To detect plasma cells and regulatory T cells, we per-
formed, respectively, intracellular  light chain (BD Biosciences,
Heidelberg, Germany) and Foxp3 (BioLegend, San Diego, CA) stain-
ing with Fix&Perm Cell Permeabilization Kit (BD Biosciences). Re-
spective isotype antibodies were used to demonstrate specific staining
of cell subpopulations as described.39 Cells were counted using Caltag
counting beads (Invitrogen, Karlsruhe, Germany) on an FACS Cali-
bur flow cytometer (BD Biosciences). For discrimination between
short- and long-lived plasma cells, we injected the MRL-Faslpr mice
with 1 mg BrdU intraperitoneally per mouse daily for 7 days before
killing.40 After surface antibody staining of splenocytes, we performed
intracellular staining for light chain and incorporatedBrdUwith the
BrdU-Flow-Kit (BD Biosciences) according to themanufacturer’s in-
structions.
Enzyme-Linked Immunosorbent Assay
Murine IL-12p70, IFN- (both OptEiA, BD) and TNF (BioLegend,
San Diego, CA) were measured by ELISA. Plasma antibodies IgG,
IgG1, IgG2a, IgG2b, IgG3, and dsDNA IgG antibodies (Bethyl Labs,
BASIC RESEARCHwww.jasn.org
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Montgomery, TX) were also measured by ELISA as described previ-
ously.11
RNA Analysis
RNA extraction and reverse transcription were performed as described
previously.10 Quantitative RT-PCR analysis was performed with Light
cycler 480 (Roche) and SYBR Green system. 18S rRNA was used as a
internal control. The following SYBR Green forward (f) and reverse (r)







AATTG3(r); TNF: 5CCACCACGCTCTTCTGTCTAC3 (f), 5AGG-
GTCTGGGCCATAGAACT3 (r); IFN: 5ACAGCAAGGCGAAAA-
AGGAT3(f), 5TGAGCTCATTGAATGCTTGG3(r); Ubd:
5AAGCAGACACAAGGATCTTTTCTT3(f), 5AAGGTCATTA-
ACCGCCATTG(r); and Cdc25a: 5TTCAGAAGACCCAATG-
GAGTG 3(f), 5CTGAATGGCGTTCATGTCAC (r).
Autoantibody Assays
Diluted plasma, 1:20, was used to detect DNA antibodies with C.
luciliae slides. The method was described previously.11 Anti-nuclear
antibody staining pattern was assessed by incubating plasma samples
(1:20 dilutions) with Hep-2 slides as described previously.11
Analysis of Tissue Injury
Spleen, lung, and kidney organs from all mice were fixed in 10%
buffered formalin and embedded in paraffin. Sections at 2-m for
periodic acid-Schiff (PAS) stains were prepared following routine
protocols. The severity of the renal lesions was graded using the indices
for activity and chronicity as described.11 IgG immunostaining was per-
formed on paraffin-embedded sections as described11 using anti-mouse
IgG (1:100, M32015, Caltag Laboratories, Burlingame, CA) and anti-
Mdm2 (1:400, Abcam). Negative controls included incubation with a
respective isotype antibody. Semiquantitative scoring of glomerular IgG
orMdm2deposits from0 to 3was performedon15 cortical glomeruli.
Tubulointerstitial Mdm2 staining was scored on 15 high-power fields,
accordingly. Ki-67 staining was performed on these paraffin-embedded
spleen sections. Measurement of urinary albumin and creatinine were
done as described previously.11
Evaluation of Peripheral Blood Cells
Peripheral bloodwas collected from themice on the day theywere killed.




Data were expressed as mean  SD. Comparison between two groups
was performed by two-tailed t test. A value ofP 0.05was considered to
be statistically significant. Survival curves were compared by Kaplan-
Meier analysis using log-rank two-tailed test. All statistical analyses were
calculated using GraphPad Prism, 4.03 version.
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